Pharmacodynamics and pharmacokinetics of furosemide-retard and furosemide-retard/triamterene

Eur J Drug Metab Pharmacokinet. 1988 Jul-Sep;13(3):161-4. doi: 10.1007/BF03189935.

Abstract

In a randomized cross-over study the saluretic effect of furosemide-retard was compared with the combination of furosemide-retard/triamterene in 10 healthy male volunteers. The combination led to a significantly stronger excretion of sodium and a significantly lower excretion of potassium than furosemide-retard. The interaction of the saluretic with the antikaliuretic was even more distinctly expressed regarding sodium related quotients. The combination furosemide-retard/triamterene differs significantly from furosemide-retard in the main considering Na+/Cl-, Na+/K+ and Na+/Mg2+ quotients. The concentration time curves for furosemide and OH-TA-sulphate in the plasma are nearly similar. Maximal plasma levels for furosemide are reached after 3.9h and for OH-TA-sulphate after 2.2h. The 'apparent' elimination half-life time for furosemide is 2.1h and the elimination half-life time for OH-TA-sulphate is 2.0h.

Publication types

  • Clinical Trial
  • Comparative Study
  • Randomized Controlled Trial

MeSH terms

  • Adult
  • Delayed-Action Preparations
  • Drug Combinations
  • Electrolytes / urine*
  • Furosemide / pharmacokinetics
  • Furosemide / pharmacology*
  • Humans
  • Male
  • Triamterene / pharmacokinetics
  • Triamterene / pharmacology*

Substances

  • Delayed-Action Preparations
  • Drug Combinations
  • Electrolytes
  • Furosemide
  • Triamterene